177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Part of paid clinical trials in Dothan, Alabama.

Sponsor
Radiopharm Theranostics, Ltd
Study ID
NCT07189871
Phase
PHASE1/PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 177Lu-BetaBart — DRUG
    BetaBart administered by intravenous (IV) infusion every 6 weeks

Study Details

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Key Dates

Start date
Feb 23, 2026
Status verified
Mar 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
61 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 177 Lu-BetaBart - Dose escalation and Phase 2a expansion
    Dose escalation and treatment and imaging period

Primary Outcome Measure

Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) [ Time Frame: 6 weeks ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Dothan Hematology & OncologyDothanAlabama36303
Juli Love
334-305-0024
BAMF HealthGrand RapidsMichigan49503
BAMF Clinical Trials Team
616-330-2735
Nebraska Cancer SpecialistsOmahaNebraska68130
Marlene Bidwell
402-691-5252
Hanna Hurz
402-691-6974
XCancerOmahaNebraska68130
Tony Romero
402-991-8468

Find similar trials in Dothan, AL

Related Studies